Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the ...
Co-Diagnostics, Inc. (NASDAQ: CODX) is a Utah-based molecular diagnostics company (headquartered in Salt Lake City) that focuses on bringing PCR testing capability closer to where patients need it. The company’s core value proposition is built around nucleic-acid detection—using PCR (polymerase chain reaction) to identify and analyze specific genetic material from ...Co-Diagnostics, Inc. (NASDAQ: CODX) is a Utah-based molecular diagnostics company (headquartered in Salt Lake City) that focuses on bringing PCR testing capability closer to where patients need it. The company’s core value proposition is built around nucleic-acid detection—using PCR (polymerase chain reaction) to identify and analyze specific genetic material from patient or sample sources—enabling rapid, real-time style testing that supports faster clinical and public-health decision-making.
Business and operating model: Co-Dx develops and sells diagnostic reagents and testing products used to detect infectious diseases. In addition to its reagent/test offerings, the company promotes a PCR platform designed to broaden access to molecular diagnostics, including point-of-care and at-home use cases. This matters from a cost and implementation perspective because decentralized testing can reduce operational friction compared with centralized laboratory workflows (e.g., logistics delays), while still aiming to deliver high-quality PCR-based results.
Products and services: The company offers the Co-Dx PCR platform and PCR diagnostic tests covering infectious disease targets such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. It also markets multiplexed test solutions for mosquito identification of diseases they may carry, along with additional molecular tools spanning applications such as liquid biopsy/cancer screening, and agricultural genomics (genetic trait identification in plant and animal genomes). Complementing these tests, Co-Dx also highlights portable diagnostic device capabilities to bring PCR-like testing to more immediate settings.
Cost and BOM/inputs (high-level): As a molecular diagnostics provider, the main bill-of-materials typically includes PCR consumables and reagents (e.g., target-specific assay components, buffers, controls) and supporting infrastructure for sample processing and detection. The company’s emphasis on reagents and an integrated PCR platform suggests a design goal of packaging diagnostic capability in a way that can be deployed broadly—potentially simplifying the procurement and operational burden for customers (clinics, testing partners, and other settings) versus assembling components from multiple sources.
Financial and investment context: Based on the provided financial snapshot, the company has negative profitability measures (e.g., negative margins and free cash flow figures in the trailing-twelve-month view), which is common for development-and-growth stages in the diagnostics sector where research and commercialization spend can be elevated. The snapshot also indicates meaningful research intensity (research and development to revenue). Market metrics provided show market capitalization in the low millions of USD range in the snapshot and a beta indicating higher volatility.
Key people and leadership: Dwight Egan serves as Chief Executive Officer and has been associated with the company since its early formation, with sources describing him as a co-founder and CEO since inception.
Wishes/trajectory: Co-Dx’s stated mission centers on democratizing access to molecular diagnostics and lowering the cost of healthcare by increasing access to PCR tools—reflecting an intent to scale availability, improve accessibility of testing, and support broader adoption of PCR beyond traditional laboratory-only pathways.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.
TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).
$622489
-84.1%
+13.8%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.
$-46.9M
-24.6%
+31.2%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.
+64.3%
-13.7%
+135.0%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).
-5025.5%
-390.9%
+40.8%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.
-7533.6%
-683.6%
+39.6%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.
$-29.8M
+0.2%
+10.2%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.
-4793.2%
-527.6%
+21.1%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.
6.0%
+51.3%
+11.8%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.
3.87x
-12.4%
-20.6%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.
Operator: Thank you for standing by. At this time, I would like to welcome everyone to the Co-Diagnostics, Inc. Second Quarter 26 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. The floor is yours.
Andrew Benson: Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight H. Egan, chief executive officer, and Brian L. Brown, chief financial officer. Earlier today, Co-Diagnostics released financial results from second quarter ended 06/30/2026. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A. Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call are not historical facts, are forward-looking statements. In addition to diagnostic test developments and clinical evaluation time lines, this includes statements concerning regulatory review and clearance. Commercialization plans and timing, international regulatory and manufacturing initiatives, financing and liquidity, and the capabilities and potential uses of the company's technology and data infrastructure. The company's Co-Dx PCR testing platform and related tests are subject to regulatory review clearance, or authorization are not currently for sale. Actual outcomes and results may differ materially from what is expressed or implied in any statement. Important factors which could cause actual results to differ materially from those in these forward-looking statements are described in the company's annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with the SEC, including under the heading Risk Factors, as well as in today's earnings release. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call to reflect the occurrence of unanticipated events. In addition, the company may discuss certain non GAAP financial measures during today's call. These non GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release issued shortly before this call which contains reconciliations to the non GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co-Diagnostics' chief executive officer, Dwight H. Egan. Dwight.
Dwight H. Egan: Thank you everyone for joining us today and for your continued support of CoDiagnostics. This past …
